17. Multiple system atrophy Clinical trials / Disease details

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02008721 (ClinicalTrials.gov)	January 2014	8/12/2013	Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach	Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)	Multiple System Atrophy	Drug: EGCG as putative neuroprotective agent;Drug: Placebo	Dr. Johannes Levin	German Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbH	Completed	18 Years	N/A	Both	92	Phase 3	Germany
2	EUCTR2012-000928-18-DE (EUCTR)	21/11/2013	28/06/2013	Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)	Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach	Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sunphenon EGCg INN or Proposed INN: EGCG Other descriptive name: GREEN TEA LEAF	Hospital of the Ludwig-Maximilians-University of Munich	NULL	Not Recruiting			Female: yes Male: yes	86	Phase 3	Germany